Silibinin Sensitizes Chemo-resistant Breast Cancer Cells to Chemotherapy

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2016 Dec 29

PMID 28027688

Citations 31

Authors

Ommoleila Molavi

Farzaneh Narimani

Farshid Asiaee

Simin Sharifi

Vahideh Tarhriz

Ali Shayanfar

Mohammadsaied Hejazi

Raymond Lai

Affiliations

Soon will be listed here.

Abstract

Context: Multiple drug resistance is the major obstacle to conventional chemotherapy. Silibinin, a nontoxic naturally occurring compound, has anticancer activity and can increase the cytotoxic effects of chemotherapy in various cancer models.

Objective: To evaluate the effects of silibinin on enhancing the sensitivity of chemo-resistant human breast cell lines to doxorubicin (DOX) and paclitaxel (PAC).

Materials And Methods: The cells were treated with silibinin (at 50 to 600 μM concentrations) and/or chemo drugs for 24 and 48 h, then cell viability and changes in oncogenic proteins were determined by MTT assay and Western blotting/RT-PCR, respectively. Flow cytometry was used to study apoptosis in the cells receiving different treatments. The antitumorigenic effects of silibinin (at 200 to 400 μM concentration) were evaluated by mammosphere assay.

Results: Silibinin exerted significant growth inhibitory effects with IC ranging from 200 to 570 μM in different cell lines. Treatment of DOX-resistant MDA-MB-435 cells with silibinin at 200 μM reduced DOX IC from 71 to 10 μg/mL and significantly suppressed the key oncogenic pathways including STAT3, AKT, and ERK in these cells. Interestingly treatment of DOX-resistant MDA-MB-435 cells with silibinin at 400 μM concentration for 48 h induced a 50% decrease in the numbers of colonies as compared with DMSO-treated cells. Treatment of PAC-resistant MCF-7 cells with silibinin at 400 μM concentration generated synergistic effects when it was used in combination with PAC at 250 nM concentration (CI = 0.81).

Conclusion: Silibinin sensitizes chemo-resistant cells to chemotherapeutic agents and can be useful in treating breast cancers.

Citing Articles

Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.

Nguyen M, Nguyen T, Le T, Le T, Chau N, Le T Heliyon. 2024; 10(20):e39229.

PMID: 39492898 PMC: 11530815. DOI: 10.1016/j.heliyon.2024.e39229.

Interactions between Dietary Antioxidants, Dietary Fiber and the Gut Microbiome: Their Putative Role in Inflammation and Cancer.

Munteanu C, Schwartz B Int J Mol Sci. 2024; 25(15).

PMID: 39125822 PMC: 11311432. DOI: 10.3390/ijms25158250.

A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.

Ray P, Islam M, Islam M, Han A, Geng P, Aziz M Front Pharmacol. 2024; 15:1349745.

PMID: 38487172 PMC: 10937417. DOI: 10.3389/fphar.2024.1349745.

Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells.

Fan C, Yuan S, Zhang Y, Nie Y, Xiang L, Luo T Biochem Biophys Rep. 2024; 37:101639.

PMID: 38288281 PMC: 10823101. DOI: 10.1016/j.bbrep.2024.101639.

Phytometabolites as modulators of breast cancer: a comprehensive review of mechanistic insights.

Sharma P, Gupta K, Khandai S, Malik S, Thareja S Med Oncol. 2024; 41(2):45.

PMID: 38172452 DOI: 10.1007/s12032-023-02269-2.

References

Kondo T . Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 2007; 3(4-5):245-50. DOI: 10.3233/cbm-2007-34-508. View

Donepudi M, Kondapalli K, Amos S, Venkanteshan P . Breast cancer statistics and markers. J Cancer Res Ther. 2014; 10(3):506-11. DOI: 10.4103/0973-1482.137927. View

Navolanic P, Steelman L, McCubrey J . EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 2003; 22(2):237-52. View

Cheung C, Gibbons N, Johnson D, Nicol D . Silibinin--a promising new treatment for cancer. Anticancer Agents Med Chem. 2009; 10(3):186-95. DOI: 10.2174/1871520611009030186. View

Pirouzpanah M, Sabzichi M, Pirouzpanah S, Chavoshi H, Samadi N . Silibilin-induces apoptosis in breast cancer cells by modulating p53, p21, Bak and Bcl-XL pathways. Asian Pac J Cancer Prev. 2015; 16(5):2087-92. DOI: 10.7314/apjcp.2015.16.5.2087. View

Ting H, Deep G, Agarwal R . Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013; 15(3):707-16. PMC: 3691417. DOI: 10.1208/s12248-013-9486-2. View

Singh R, Raina K, Sharma G, Agarwal R . Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008; 14(23):7773-80. PMC: 2639624. DOI: 10.1158/1078-0432.CCR-08-1309. View

Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T . Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 2013; 25(12):2625-33. DOI: 10.1016/j.cellsig.2013.08.028. View

Real P, Sierra A, de Juan A, Segovia J, Lopez-Vega J, Fernandez-Luna J . Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002; 21(50):7611-8. DOI: 10.1038/sj.onc.1206004. View

10.

Turkson J, Kim J, Zhang S, Yuan J, Huang M, Glenn M . Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004; 3(3):261-9. View

11.

Scully O, Bay B, Yip G, Yu Y . Breast cancer metastasis. Cancer Genomics Proteomics. 2012; 9(5):311-20. View

12.

Sharifi S, Barar J, Hejazi M, Samadi N . Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. Asian Pac J Cancer Prev. 2014; 15(20):8617-22. DOI: 10.7314/apjcp.2014.15.20.8617. View

13.

Tan F, Putoczki T, Stylli S, Luwor R . The role of STAT3 signaling in mediating tumor resistance to cancer therapy. Curr Drug Targets. 2014; 15(14):1341-53. DOI: 10.2174/1389450115666141120104146. View

14.

Steelman L, Navolanic P, Chappell W, Abrams S, Wong E, Martelli A . Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011; 10(17):3003-15. PMC: 3218601. DOI: 10.4161/cc.10.17.17119. View

15.

Baguley B . Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010; 46(3):308-16. DOI: 10.1007/s12033-010-9321-2. View

16.

Comelli M, Mengs U, Schneider C, Prosdocimi M . Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007; 6(2):120-9. DOI: 10.1177/1534735407302349. View

17.

Dhillon A, Hagan S, Rath O, Kolch W . MAP kinase signalling pathways in cancer. Oncogene. 2007; 26(22):3279-90. DOI: 10.1038/sj.onc.1210421. View

18.

Orlandi L, Bearzatto A, Abolafio G, De Marco C, Daidone M, Zaffaroni N . Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer. 1999; 81(2):252-60. PMC: 2362863. DOI: 10.1038/sj.bjc.6690685. View

19.

Flaig T, Gustafson D, Su L, Zirrolli J, Crighton F, Harrison G . A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2006; 25(2):139-46. DOI: 10.1007/s10637-006-9019-2. View

20.

Siddiquee K, Turkson J . STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008; 18(2):254-67. PMC: 2610254. DOI: 10.1038/cr.2008.18. View